The UCLA Prostate Cancer SPORE program is a multidisciplinary and translational research program whose purpose is to understand the biology of prostate cancer and to develop more effective methods for prevention, diagnosis and treatment. This mission will be accomplished through (1) five major research projects focused on the application of basic and population science to the prevention, diagnosis and treatment of prostate cancer, and (2) the recruitment and development of new prostate cancer researchers and research projects through career development and developmental research projects. The UCLA prostate SPORE leverages the exciting resources and programs at UCLA, its sister institutions, as well as Cedars Sinai and City of Hope Cancer Center, to improve the care of men with prostate cancer. It collaborates extensively with other SPORE institutions and the SPORE program at the NCI to advance local and national initiatives. Over the first four years of funding, the UCLA SPORE has made significant strides, such as the development and translation of PSCA antibody therapy to the clinic, the demonstration at the molecular level that mTOR antagonism down-regulates the PIS kinase-PTEN-Akt pathway in men with PTEN null tumors, and the initiation of a novel dietary prevention trial in men undergoing prostate surgery. In this application, the five major projects are as follows: 1) Project 1: Bioengineered Antibodies Against Prostate Stem Cell Antigen (PSCA) for Prostate Cancer Imaging (Project Leaders: Anna Wu, M.D. and Robert Reiter, M.D; Project co-Leader, Robert Figlin, M.D.); 2) Project 2: Exploiting PIS Pathway Inhibitor Therapy in Prostate Cancer (Project Leaders: Hong Wu, M.D, Ph.D. and Charles Sawyers, M.D; Project co-Leaders, Robert Reiter, M..D. and Howard Scher, M.D; 3) Project 3: Lymphangiogenesis and Metastasis in Prostate Cancer (Project Leader: Lily Wu, M.D., Ph.D; Project co-Leader: David Agus, M.D.); 4) Project 4: Evaluating the role of IGFBP-3 therapy in men with prostate cancer (Project Leader: Pinchas Cohen, M.D.; Project co- Leaders: Alan Pantuck, M.D and Kuk-Wha Lee, M.D., Ph.D; 5) Project 5: Dietary Fat Modulation and targeted Therapies for Prostate Cancer Prevention (Project Leader: William Aronson, M.D.; Project co- Leaders: Pinchas Cohen, M.D. and Harvey Herschman, Ph.D.) ? ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA092131-07
Application #
7485695
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Program Officer
Hruszkewycz, Andrew M
Project Start
2001-07-01
Project End
2012-06-30
Budget Start
2008-08-22
Budget End
2009-06-30
Support Year
7
Fiscal Year
2008
Total Cost
$2,346,813
Indirect Cost
Name
University of California Los Angeles
Department
Surgery
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099
Henning, Susanne M; Galet, Colette; Gollapudi, Kiran et al. (2018) Phase II prospective randomized trial of weight loss prior to radical prostatectomy. Prostate Cancer Prostatic Dis 21:212-220
Miller, Eric T; Salmasi, Amirali; Reiter, Robert E (2018) Anatomic and Molecular Imaging in Prostate Cancer. Cold Spring Harb Perspect Med 8:

Showing the most recent 10 out of 339 publications